Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Researcher

Dengfeng Wang

Sichuan Cancer Hospital

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 18, 2026 · JOURNAL ARTICLE

Serplulimab combined with bevacizumab and chemotherapy as first-line treatment for recurrent or metastatic cervical cancer (ASTRUM-CC01): a phase II trial

Frontiers in Immunology

Single-arm phase II trial showing encouraging ORR and PFS in a small cohort, but lacks a control arm and mature OS data; results warrant phase III confirmation but do not yet change practice.

PromisingGuonan Zhang Chunyan Wang Hong Liu

Reported

Sample size evaluable43

Objective response rate75.00%

ORR 95% CI60.40–86.36

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support